Alpha Teknova, Inc. (TKNO)
NASDAQ: TKNO · IEX Real-Time Price · USD
2.460
-0.040 (-1.60%)
At close: Mar 27, 2024, 4:00 PM
2.500
+0.040 (1.63%)
After-hours: Mar 27, 2024, 4:00 PM EDT
Company Description
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics.
The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions.
The company was founded in 1996 and is headquartered in Hollister, California.
Alpha Teknova, Inc.
Country | United States |
Founded | 1996 |
IPO Date | Jun 25, 2021 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 285 |
CEO | Stephen Gunstream |
Contact Details
Address: 2451 Bert Drive Hollister, California 95023 United States | |
Phone | (831) 637-1100 |
Website | teknova.com |
Stock Details
Ticker Symbol | TKNO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $16.00 |
CIK Code | 0001850902 |
CUSIP Number | 02080L102 |
ISIN Number | US02080L1026 |
Employer ID | 94-3368109 |
SIC Code | 2835 |
Key Executives
Name | Position |
---|---|
Stephen Gunstream | President, Chief Executive Officer and Director |
Matthew C. Lowell | Chief Financial Officer |
Damon A. Terrill | General Counsel, Chief Compliance Officer and Secretary |
Jennifer Henry | Senior Vice President of Marketing |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 27, 2024 | 10-K | Annual Report |
Mar 11, 2024 | 8-K | Current Report |
Feb 22, 2024 | DEF 14C | Filing |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 16, 2024 | 8-K | Current Report |
Nov 13, 2023 | 10-Q | Quarterly Report |
Nov 9, 2023 | 8-K | Current Report |
Nov 9, 2023 | 424B3 | Prospectus |
Nov 7, 2023 | EFFECT | Notice of Effectiveness |